Circana: GLP-1 medication users will account for 35% of all U.S. food and beverage units sold by 2030
This shift directly impacts purchasing decisions, with consumers altering their baskets to align with new dietary preferences.
GLP-1
Shotsy names Eric Perakslis as CSO to advance safe, science-backed GLP-1 support
Internationally recognized researcher in medical safety and privacy, former Chief Scientist and CIO at the FDA, brings scientific and regulatory leadership to Shotsy.
GlobalData reports Ozempic price cut to slow consumer shift toward alternative treatments
The company aims to make FDA approved semaglutide therapies safer and more financially accessible, compared to compounded weight-loss alternatives.
UVA Health experts warn GLP-1 drugs may not provide key long-term weight-loss benefit
Doctors may need to consider recommending exercise programs or develop other approaches, such as nutrition supplements or complementary medications, to help GLP-1 patients get the full cardiorespiratory benefits of substantial weight loss over the long-run, the researchers say.
WeightWatchers and Novo Nordisk expand partnership
WeightWatchers clinic members can access FDAapproved Wegovy for $299 in July.
Scripta Insights launches GLP-1 Navigator
New member app feature delivers trusted, clinician-backed guidance as millions face GLP-1 access setbacks after CVS Caremark drops Zepbound and WeightWatchers files for bankruptcy.
New study challenges GLP-1 norms with strong results on a fraction of the usual dose
In one of the largest and longest real-world obesity studies to date, Embla tracked nearly 2,700 adults over 64 weeks and achieved 16.7% average weight loss using 66% less semaglutide than typical U.S. doses.
Charles Barkley teams with Ro as GLP-1 Celebrity Ambassador
The NBA legend is spotlighting convenient access to weight loss treatment with Ro.
New report from GoodRx tracks changes in GLP-1 insurance coverage
In 2025, the number of people without commercial insurance coverage for these medications surged significantly. Zepbound saw a 14% increase since 2024, leaving 4.9 million people without coverage, and Ozempic saw a 22% increase, affecting another 1.1 million people.